You want to put a few thousand dollars into a biotech company, but you're not a scientist. We read the published research for you and tell you, in plain language, whether the company's science is realistic — before you invest.
Between a promising paper and a manufacturable therapy lies a chasm of unvalidated assumptions — scale-up risk, off-target effects, irreproducible data. Capital flows toward the narrative. We follow the evidence.
Deep-dive technical auditing of clinical data packages, experimental design, and biological mechanism validation across pre-clinical and clinical assets.
Quantifying "science-risk" before capital deployment — IP robustness, pipeline feasibility, and competitive positioning.
Specialized advisory for CAR-T, CRISPR, viral vectors and mRNA — focused on CMC hurdles and biological translation.
Continuous horizon-scanning for disruptive modalities and emerging shifts that could impact your portfolio's value.
"The gap between clinical success and commercial viability is where most cell and gene therapies fail. Rigorous manufacturing data is the only true currency."
All inquiries are treated with strict confidentiality under NDA upon request.